{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029156","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.843230+00:00","generated_at":"2026-06-11T08:18:31.177588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cocrystal Pharma Q2 net loss $4.2M; cash $32.4M; advances antiviral pipeline","bullets":["Net loss $4.2M ($0.41/share) vs $24.4M ($3.00) in Q2 2022, which included $19.1M goodwill impairment and legal settlement.","Cash $32.4M at June 30, 2023 vs $37.1M at Dec 31, 2022; management expects sufficient for 12 months.","On track to initiate Phase 2a trial for CC-42344 (influenza A) in H2 2023 pending UK MHRA clearance.","Selected novel protease inhibitor CDI-988 as lead oral norovirus candidate; Phase 1 cleared by Australian regulator.","Completed $4.0M private placement of common stock with directors Fred Hassan and Phillip Frost."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029156","json":"https://secwatch.observer/filing/0001493152-23-029156.json","markdown":"https://secwatch.observer/filing/0001493152-23-029156.md","text":"https://secwatch.observer/filing/0001493152-23-029156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/0001493152-23-029156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:18:31.177588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f9a2427156c3beb42e82dfa72c0b9c23b21daa0","claim":"Cocrystal Pharma, Inc. reported financial results for the three and six months ended June 30, 2023.","evidence_excerpt":"Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/0001493152-23-029156-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}